RevMed’s pancreatic cancer win strengthens the case for targeting RAS(ON)

As the KRAS-targeting pipeline grows, Revolution Medicines’ Phase III win with daraxonrasib in pancreatic cancer strengthens the case for targeting RAS(ON), suggesting active-state inhibition can deliver meaningful efficacy in a disease where RAS has long been central to the biology but hard to drug.

The company has not disclosed when it expects to file an NDA, but daraxonrasib has already received a Commissioner’s National Priority Voucher that could support an accelerated review timeline. ...